Rapiblyk: Dosage Form, Projected Sales, NCE-1 Date | Landiolol

Rapiblyk

Rapiblyk is an IV beta-blocker used in hospitals to quickly control heart rate during acute supraventricular tachycardia (like atrial fibrillation or flutter). Its ultra-rapid action slows the heart without significantly lowering blood pressure.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Landiolol
Innovator :

AOP ORPHAN PHARMACEUTICALS AG
Approval Date :

22-Nov-24
NCE-1 Date :

22-Nov-28
NCE Date :

22-Nov-29
Dosage Form :

Intravenous Powder Injection
Strength :

280MG BASE/VIAL
Therapeutic Category :

Cardiovascular Agents
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

NA
2026 :

NA
2027 :

NA
2028 :

NA
2029 :

NA
2030 :

NA
2031 :

NA

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Rapiblyk

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?